To determine whether elotuzumab-mediated NK cell activation and myeloma cell killing resulted from ligation of SLAMF7 and/or CD16, we tested the effects of Fc deficient elotuzumab F(ab′)2 on NK cell activation and myeloma cell killing in the co-cultures. Here, SLAMF7 is linked to plasma cell myeloma.